Brugada syndrome: Recent advances and controversies

Current Cardiology Reports

Volumn 10, Issue 5, 2008, Pages 376-383

  Antzelevitch, Charles ^a   Nof, Eyal ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJMALINE; ANTIPYRETIC AGENT; CALCIUM CHANNEL; CILOSTAZOL; FLECAINIDE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; ISOPRENALINE; PILSICAINIDE; PROCAINAMIDE; QUINIDINE; SALVIA MILTIORRHIZA EXTRACT; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; ANTIARRHYTHMIC AGENT; MUSCLE PROTEIN; SCN5A PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; AUTOSOMAL DOMINANT INHERITANCE; BRUGADA SYNDROME; CLINICAL FEATURE; DEFIBRILLATOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; ELECTROCARDIOGRAM; FEVER; GASTROINTESTINAL SYMPTOM; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEART PACING; HEREDITY; HUMAN; IMPLANTATION; INCIDENCE; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; ELECTROCARDIOGRAPHY; GENETICS; SUDDEN DEATH;

ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; HUMANS; MUSCLE PROTEINS; RISK FACTORS; SODIUM CHANNELS;

EID: 58149109872     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0060-y     Document Type: Review

References (90)

1. Brugada P, Brugada J: Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992, 20: 1391-1396.
2. Krishnan SC, Antzelevitch C: Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium. Circ Res 1991, 69: 277-291.
3. Krishnan SC, Antzelevitch C: Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation 1993, 87: 562-572.
4. Yan GX, Antzelevitch C: Cellular basis for the electrocardiographic J wave. Circulation 1996, 93: 372-379.
5. Miyazaki T, Mitamura H, Miyoshi S, et al.: Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996, 27: 1061-1070.
6. Wilde AA, Antzelevitch C, Borggrefe M, et al.: Proposed diagnostic criteria for the Brugada syndrome: Consensus report. Circulation 2002, 106: 2514-2519.
7. Antzelevitch C, Brugada P, Borggrefe M, et al.: Brugada Syndrome. Report of the second consensus conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005, 111: 659-670.
8. Chen Q, Kirsch GE, Zhang D, et al.: Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 1998, 392: 293-296.
9. Antzelevitch C, Brugada P, Brugada J, et al.: The Brugada Syndrome: From Bench to Bedside. Oxford: Blackwell Futura; 2005.
10. Tan HL: Sodium channel variants in hEart disease: expanding horizons. J Cardiovasc Electrophysiol 2006, 17(Suppl 1): S151-S157.
11. Hong K, Guerchicoff A, Pollevick GD, et al.: Cryptic 5′ splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol 2005, 38: 555-560.
12. Bezzina CR, Shimizu W, Yang P, et al.: Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation 2006, 113: 338-344.
13. Yang P, Koopmann TT, Pfeufer A, et al.: Polymorphisms in the cardiac sodium channel promoter displaying variant in vitro expression activity. Eur J Hum Genet 2008, 16: 350-357.
14. London B, Michalec M, Mehdi H, et al.: Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007, 116: 2260-2268.
15. Van Norstrand DW, Valdivia CR, Tester DJ, et al.: Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome. Circulation 2007, 116: 2253-2259.
16. Skinner JR, Chung SK, Montgomery D, et al.: Near-miss SIDS due to Brugada syndrome. Arch Dis Child 2005, 90: 528-529.
17. Antzelevitch C, Pollevick GD, Cordeiro JM, et al.: Loss-offunction mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007, 115: 442-449.
18. Cordeiro JM, Barajas-Martinez H, Hong K, et al.: Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation 2006, 114: 2026-2033.
19. Antzelevitch C: Brugada syndrome. Pacing Clin Electrophysiol 2006, 29: 1130-1159.
20. Probst V, Denjoy I, Meregalli PG, et al.: Clinical aspects and prognosis of Brugada syndrome in children. Circulation 2007, 115: 2042-2048.
21. Junttila MJ, Gonzalez M, Lizotte E, et al.: Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation 2008, 117: 1890-1893.
22. Wolpert C, Echternach C, Veltmann C, et al.: Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2005, 2: 254-260.
23. Peters S, Trummel M, Denecke S, et al.: Results of ajmaline testing in patients with arrhythmogenic right ventricular dysplasia-cardiomyopathy. Int J Cardiol 2004, 95: 207-210.
24. Priori SG, Napolitano C: Management of patients with Brugada syndrome should not be based on programmed electrical stimulation. Circulation 2005, 112: 285-291.
25. Abello M, Merino JL, Peinado R, et al.: Negative flecainide test in Brugada syndrome patients with previous positive response. Europace 2006, 8: 899-900.
26. Shimizu W, Matsuo K, Takagi M, et al.: Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: Clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 2000, 11: 396-404.
27. Miyamoto K, Yokokawa M, Tanaka K, et al.: Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome. Am J Cardiol 2007, 99: 53-57.
28. Shin SC, Ryu S, Lee JH, et al.: Prevalence of the Brugada-type ECG recorded from higher intercostal spaces in healthy Korean males. Circ J 2005, 69: 1064-1067.
29. Brugada J, Brugada R, Brugada P: Right bundle-branch block and ST-segment elevation in leads V1 through V3. A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998, 97: 457-460.
30. Brugada P, Brugada R, Brugada J: Patients with an asymptomatic Brugada electrocardiogram should undergo pharmacological and electrophysical testing. Circulation 2005, 112: 279-285.
31. Brugada P, Brugada R, Brugada J: Response to Priori and Napolitano. Circulation 2005, 112: 292.
32. Eckardt L, Probst V, Smits JP, et al.: Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada Syndrome. Circulation 2005, 111: 257-263.
33. Gehi AK, Duong TD, Metz LD, et al.: Risk stratification of individuals with the Brugada electrocardiogram: A meta-analysis. J Cardiovasc Electrophysiol 2006, 17: 577-583.
34. Ohkubo K, Watanabe I, Takagi Y, et al.: Electrocardiographic and electrophysiologic characteristics in patients with Brugada type electrocardiogram and inducible ventricular fibrillation. Circ J 2007, 71: 1437-1441.
35. Paul M, Gerss J, Schulze-Bahr E, et al.: Role of programmed ventricular stimulation in patients with Brugada syndrome: A meta-analysis of worldwide published data. Eur Heart J 2007, 28: 2126-2133.
36. Yan GX, Antzelevitch C: Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999, 100: 1660-1666.
37. Fish JM, Antzelevitch C: Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 2004, 1: 210-217.
38. Fish JM, Antzelevitch C: Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome. J Cardiovasc Electrophysiol 2008, 19: 301-308.
39. Carlsson J, Erdogan A, Schulte B, et al.: Possible role of epicardial left ventricular programmed stimulation in Brugada syndrome. Pacing Clin Electrophysiol 2001, 24: 247-249.
40. Junttila MJ, Brugada P, Hong K, et al.: Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol 2008, 19: 380-383.
41. Meregalli PG, Ruijter JM, Hofman N, et al.: Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol 2006, 17: 857-864.
42. Sarkozy A, Boussy T, Kourgiannides G, et al.: Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007, 28: 334-344.
43. Sacher F, Probst V, Iesaka Y, et al.: Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: A multicenter study. Circulation 2006, 114: 2317-2324.
44. Bordachar P, Reuter S, Garrigue S, et al.: Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004, 25: 879-884.
45. Francis J, Antzelevitch C: Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol 2008, 51: 1149-1153.
46. Babai Bigi MA, Aslani A, Shahrzad S: Clinical predictors of atrial fibrillation in Brugada syndrome. Europace 2007, 1: 947-950.
47. Kusano KF, Taniyama M, Nakamura K, et al.: Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol 2008, 51: 1169-1175.
48. Viskin S: Brugada syndroDe in children: don't ask, don't tell? Circulation 2007, 115: 1970-1972.
49. Antzelevitch C, Brugada P, Brugada J, et al.: The Brugada Syndrome. Armonk, NY: Futura Publishing Company; 1999. [Clinical Approaches to Tachyarrhythmias Series, #10.]
50. Belhassen B, Viskin S: Pharmacologic approach to therapy of Brugada syndrome: Quinidine as an alternative to ICD therapy? In The Brugada Syndrome: From Bench to Bedside. Edited by Antzelevitch C, Brugada P, Brugada J, Brugada R. Oxford: Blackwell Futura; 2004:202-211.
51. Ohgo T, Okamura H, Noda T, et al.: Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007, 4: 695-700.
52. Belardinelli L, Antzelevitch C, Vos MA: Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003, 24: 619-625.
53. Antzelevitch C: Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 2007, 9: Iv4-iv15.
54. Marquez M, Salica G, Hermosillo AG, et al.: Ionic basis of pharmacological therapy in Brugada syndrome. J Cardiovasc Electrophysiol 2007, 18: 234-240.
55. Tsuchiya T, Ashikaga K, Honda T, et al.: Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002, 13: 698-701.
56. Sergeev P, da Silva R, Lucchinetti E, et al.: Trigger-dependent gene expression profiles in cardiac preconditioning: Evidence for distinct genetic programs in ischemic and anesthetic preconditioning. Anesthesiology 2004, 100: 474-488.
57. Abud A, Bagattin D, Goyeneche R, et al.: Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2006, 17: 210-212.
58. Fish JM, Welchons DR, Kim YS, et al.: Dimethyl lithospermate B, an extract of danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 2006, 113: 1393-1400.
59. Haissaguerre M, Extramiana F, Hocini M, et al.: Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003, 108: 925-928.
60. Kataoka H: Electrocardiographic patterns of the Brugada syndrome in right ventricular infarction/ischemia. Am J Cardiol 2000, 86: 1056.
61. Wang K, Asinger RW, Marriott HJ: ST-segment elevation in conditions other than acute myocardial infarction. N Engl J Med 2003, 349: 2128-2135.
62. Myers GB: Other QRS-T patterns that may be mistaken for myocardial infarction. IV. Alterations in blood potassium; myocardial ischemia; subepicardial myocarditis; distortion associated with arrhythmias. Circulation 1950, 2: 75-93.
63. Ortega-Carnicer J, Benezet J, Ruiz-Lorenzo F, et al.: Transient Brugada-type electrocardiographic abnormalities in renal failure reversed by dialysis. Resuscitation 2002, 55: 215-219.
64. Douglas PS, Carmichael KA, Palevsky PM: Extreme hypercalcemia and electrocardiographic changes. Am J Cardiol 1984, 54: 674-675.
65. Sridharan MR, Horan LG: Electrocardiographic J wave of hypercalcemia. Am J Cardiol 1984, 54: 672-673.
66. Thiene G, Basso C, Calabrese F, et al.: Twenty years of progress and beckoning frontiers in cardiovascular pathology. Cardiovasc Pathol 2005, 14: 165-169.
67. Hong K, Brugada J, Oliva A, et al.: Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 2004, 110: 3023-3027.
68. Corrado D, Basso C, Buja G, et al.: Right bundle branch block, right precordial ST-segment elevation, and sudden death in young people. Circulation 2001, 103: 710-717.
69. Corrado D, Nava A, Buja G, et al.: Familial cardiomyopathy underlies syndrome of right bundle branch block, ST segment elevation and sudden death. J Am Coll Cardiol 1996, 27: 443-448.
70. Abbott JA, Cheitlin MD: The nonspecific camel-hump sign. JAMA 1976, 235: 413-414.
71. Hersch C: Electrocardiographic changes in head injuries. Circulation 1961, 23: 853-860.
72. Tarin N, Farre J, Rubio JM, et al.: Brugada-like electrocardiographic pattern in a patient with a mediastinal tumor. Pacing Clin Electrophysiol 1999, 22: 1264-1266.
73. Atarashi H, Ogawa S: New ECG criteria for high-risk Brugada syndrome. Circ J 2003, 67: 8-10.
74. Morita H, Takenaka-Morita S, Fukushima-Kusano K, et al.: Risk stratification for asymptomatic patients with Brugada syndrome. Circ J 2003, 67: 312-316.
75. Takagi M, Tatsumi H, Yoshiyama M: Approach to the asymptomatic patients with Brugada syndrome. Indian Pacing Electrophysiol J 2007, 7: 73-76.
76. Bigi MA, Aslani A, Aslani A: Significance of cardiac autonomic neuropathy in risk stratification of Brugada syndrome. Europace 2007 Dec 18 (Epub ahead of print).
77. Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, et al.: Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006, 47: 1828-1834.
78. Nishizaki M, Fujii H, Sakurada H, et al.: Spontaneous T wave alternans in a patient with Brugada syndrome-responses to intravenous administration of class I antiarrhythmic drug, glucose tolerance test, and atrial pacing. J Cardiovasc Electrophysiol 2005, 16: 217-220.
79. Tada H, Nogami A, Shimizu W, et al.: ST segment and T wave alternans in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2000, 23: 413-415.
80. Chinushi M, Washizuka T, Okumura H, et al.: Intravenous administration of class I antiarrhythmic drugs induced T wave alternans in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2001, 12: 493-495.
81. Chinushi Y, Chinushi M, Toida T, et al.: Class I antiarrhythmic drug and coronary vasospasm-induced T wave alternans and ventricular tachyarrhythmia in a patient with Brugada syndrome and vasospastic angina. J Cardiovasc Electrophysiol 2002, 13: 191-194.
82. Takagi M, Doi A, Takeuchi K, et al.: Pilsicanide-induced marked T wave alternans and ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002, 13: 837.
83. Ohkubo K, Watanabe I, Okumura Y, et al.: Intravenous administration of class I antiarrhythmic drug induced T wave alternans in an asymptomatic Brugada syndrome patient. Pacing Clin Electrophysiol 2003, 26: 1900-1903.
84. Morita H, Morita ST, Nagase S, et al.: Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 2003, 42: 1624-1631.
85. Morita H, Nagase S, Kusano K, et al.: Spontaneous T wave alternans and premature ventricular contractions during febrile illness in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002, 13: 816-818.
86. Tada T, Kusano KF, Nagase S, et al.: Clinical significance of macroscopic T-wave alternans after sodium channel blocker administration in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2008, 19: 56-61.
87. Babai Bigi MA, Aslani A, Shahrzad S: AVR sign as a risk factor for life-threatening arrhythmic events in patients with Brugada syndrome. Heart Rhythm 2007, 4: 1009-1012.
88. Babaee Bigi MA, Moaref AR, Aslani A: Interventricular mechanical dyssynchrony: A novel marker of cardiac events in Brugada syndrome. Heart Rhythm 2008, 5: 79-82.
89. Watanabe H, Koopmann TT, Le Scouarnec S, et al.: Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008, 118: 2260-2268.
90. Delpón E, Cordeiro JM, Núñez L, et al.: Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circulation Arrhythmia and Electrophysiology 2008 (in press).